The Data Protection debate has returned to the spotlight as global pharmaceutical companies renew their demand for stronger regulatory safeguards in India.
The Drug manufacturers sector could see a major regulatory change in the United States. The US FDA has proposed a new rule to simplify registration for certain companies using distributed manufacturing models.
India’s pharmaceutical sector witnessed a dynamic week marked by drug innovation, regulatory tightening, global collaborations, and infrastructure investments
Reproductive rights have come sharply into focus in India as the National Commission for Women (NCW) initiates a comprehensive review of the regulatory framework
The expanding field of peptide-based inquiry continues to uncover fragments whose functional identities extend far beyond their origins. Among these, BPC-157, derived from a segment
The Ebola concern in the Democratic Republic of the Congo has entered a new phase. Health officials are now focusing less on the official case count.
India has marked a significant milestone in global eye care as the WHO redesignates the L V Prasad Eye Institute as the Centre for Prevention of Blindness until 2030
India’s healthcare ecosystem is witnessing a steady transformation, driven by rising research and development (R&D) initiatives and increased investments in scientific infrastructure
The government has proposed bringing several alcohol-based medicinal products under Schedule H1. The move aims to prevent misuse while ensuring patients continue to access genuine treatment.
India's Drug Deal Reform is set to tighten the country's public drug procurement system. The move aims to stop companies with canceled manufacturing licenses from securing government contracts. Officials believe the Drug Deal Reform will close...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")